A novel antifibrotic strategy utilizing conditioned media obtained from miR-150-transfected adipose-derived stem cells: validation of an animal model of liver fibrosis

Kwang Yeol Paik1, Kee-Hwan Kim2,3, Jung Hyun Park4, Jae Im Lee2, Ok-Hee Kim3,5, Ha-Eun Hong5, Haeyeon Seo5, Ho Joong Choi5, Joseph Ahn5, Tae Yun Lee5 and Say-June Kim3,5

Abstract
The limitations of stem cells have led researchers to investigate the secretome, which is the secretory materials in stem cells, since the principal mechanism of action of stem cells is mediated by the secretome. In this study, we determined the antifibrotic potential of the secretome released from miR-150-transfected adipose-derived stromal cells (ASCs). The secretome released from ASCs that were transfected with antifibrotic miR-150 was obtained (referred to as the miR-150 secretome). To validate the antifibrotic effects of the miR-150 secretome, we generated in vitro and in vivo models of liver fibrosis by treating human hepatic stellate cells (LX2 cells) with thioacetamide (TAA) and subcutaneous injection of TAA into mice, respectively. In the in vitro model, more significant reductions in the expression of fibrosis-related markers, such as TGFβ, Col1A1, and α-SMA, were observed by using the miR-150 secretome than the control secretome, specifically in TAA-treated LX2 cells. In the in vivo model, infusion of the miR-150 secretome into mice with liver fibrosis abrogated the increase in serum levels of systemic inflammatory cytokines, such as IL-6 and TNF-α, and induced increased expression of antifibrotic, proliferative, and antioxidant activity markers in the liver. Our in vitro and in vivo experiments indicate that the miR-150 secretome has the potential to induce the release of secretory materials with enhanced antifibrotic, proliferative, and antioxidant properties.

Introduction
Advanced liver fibrosis is one of the major causes of mortality and morbidity worldwide because it leads to liver cirrhosis, portal hypertension, hepatocellular carcinoma, and ultimately hepatic failure. Currently, liver transplantation is considered the only curative option. In the past few decades, advances in stem cell research have provided hope that stem cells could ameliorate liver fibrosis. However, despite several promising results in clinical trials1-7, it appears that it will take time for this approach to be applied in clinical practice. Safety concerns are one of the main obstacles to the clinical application of stem cells because the stability of transplanted stem cells cannot be guaranteed. To overcome safety concerns, several researchers have turned to their attention to the secretome, which are the molecules that are secreted or surface-shed by stem cells8,9. Numerous studies have demonstrated that the secretome has similar potential to that of stem cells because the principal mechanism of action of these cells is mediated by the secretome10-17. We have also performed several experiments that validated the therapeutic
potential of the secretome, especially for the treatment of liver diseases, and have concluded that the secretome and stem cells have similar therapeutic potential, at least for improving hepatic failure\textsuperscript{18–23}.

Although the secretome has some degree of regenerative properties, the naïve secretome does not sufficiently improve advanced liver diseases. To improve the therapeutic potential of the stem cell-derived secretome, several modifications have been attempted, including alterations in the physicochemical culture environment and genetic modifications of stem cells\textsuperscript{17,18,20,24}. There are advantages in utilizing anti-fibrotic microRNAs (miRNAs); miRNAs are small non-coding RNA molecules (~22 nucleotides) that alter gene expression at the posttranscriptional level, resulting in altered protein synthesis. miRNAs are involved in fibrosis, acting as profibrotic or anti-fibrotic miRNAs. Of these, miR-150 is a representative anti-fibrotic miRNA that inhibits the activation of hepatic stellate cells (HSCs)\textsuperscript{25–31}. We hypothesized that transfection of miR-150 into adipose-derived stem cells (ASCs) will promote the release of a secretome with robust anti-fibrotic properties. Accordingly, we generated a secretome from miR-150-transfected ASCs (miR-150 secretome) and determined its anti-fibrotic properties using both in vitro and in vivo experimental models of liver fibrosis.

Materials and methods

Preparation of cells

LX-2 human stellate cells were kindly donated by Dr. Won-il Jeong of KAIST Biomedical Research of Korea. LX-2 cells were maintained in DMEM (Dulbecco’s modified Eagle’s medium; Thermo Fisher Scientific, Carlsbad, CA). The medium was supplemented with 10% FBS (fetal bovine serum; Gibco BRL, Carlsbad, CA) and 1% antibiotics (Thermo Fisher Scientific) at 37 °C. Human adipose-derived stromal cells (ASCs) were obtained from liposaparated fat with informed consent of the volunteers. This research was approved by the Institutional Review Board (IRB number: 700069-201407-BR-002-01) of Huirim BioCell Co. Ltd. (Seoul, Korea). Liposaparated fat was digested by 0.1% collagenase (Sigma-Aldrich, St. Louis, MO) in saline and collected after centrifugation. The cells were plated in culture flasks in low-glucose DMEM supplemented with 10% FBS (Thermo Fisher Scientific), 100 U/mL penicillin (Thermo Fisher Scientific), and 0.1 mg/mL streptomycin (Thermo Fisher Scientific). ASCs were incubated at 37 °C in a humidified chamber containing 5% carbon dioxide, and the medium was changed every 3 days.

miR-150 transfection into ASCs

ASCs were transfected with miRNA-150 (miR-150; Exiqon, Germantown, MD) using Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific) in medium. After 72 h of transfection, the cells were morphologically observed by inverted microscopy. The cell numbers were counted with an automatic cell counter (Countess; Invitrogen, San Diego, CA) using trypan blue solution. Transfected cells were processed for cell phenotyping or were differentiated with three-lineage induction.

For cell characterization, the immunophenotype of naïve or transfected ASCs was determined by flow cytometry analysis (Cytomics FC500 flow cytometer, Beckman Coulter, Fullerton, CA) using FITC-conjugated CD31, CD45, and CD73 antibodies and PE-CD105 antibodies (BD Pharmingen, San Jose, CA). Isotype controls were performed with antibodies against IgG. In addition, the adipogenic, osteogenic, and chondrogenic differentiation ability of the naïve and transfected ASCs was determined as previously described\textsuperscript{32,33}.

miRNA extraction and real-time PCR

Total miRNAs were prepared from ASCs and exosomes using a miRNeasy mini kit (Qiagen, Hilden, Germany). Total exosomes were prepared from ASC culture supernatant using total exosome isolation reagent (Thermo Fisher Scientific). RNA (250 ng) was reverse transcribed using a miRCURY LNA Universal RT microRNA PCR kit (Qiagen). Real-time PCR was performed using miR-150-specific primers (Qiagen). qRT-PCR was performed on a Step One Plus real-time PCR system (Life Technologies, Carlsbad, CA). After normalization to U6 snRNA (Qiagen), expression levels of each target miRNA were calculated using the comparative cycle threshold method.

Western blot analysis

LX-2 cells and liver specimens were obtained from mice, lysed using an EZRIPA lysis kit (ATTO Corporation; Tokyo, Japan) and quantified by Bradford reagent (BioRad, Hercules, CA). Proteins were visualized by western blot analysis using primary antibodies (1:1000 dilution) at 4 °C overnight and then HRP-conjugated secondary antibodies (1:2000 dilution) for 1 h at 25 °C. Primary antibodies against PCNA (proliferating cell nuclear antigen), TGF-β1 (transforming growth factor-β1), α-SMA (alpha-smooth muscle actin), TIMP-1 (metalloproteinase inhibitor 1), MMP2 (matrix metalloproteinase 2), COI1A1 (collagen type I alpha 1 chain), and β-actin and horseradish peroxidase (HRP)-conjugated secondary antibodies were obtained from Cell Signaling Technology (Beverly, MA). Specific immune complexes were detected using Western Blotting Plus chemiluminescence reagent (Millipore, Bedford, MA).

Animal study using experimental mice

We used 5-week-old male BALB/c mice ( Orient Bio, Seongnam, Korea) in this study. Animal studies were carried out in compliance with the guidelines of the Institute for Laboratory Animal Research of Korea (IRB No: CUMC-2018-0175-01). We then compared the effects of MCM in an
in vivo model of TAA-induced hepatic fibrosis. The in vivo model was generated by subcutaneous injection of TAA (200 mg/kg, three times a week for 5 weeks) into the mice. The mice were intravenously infused with normal saline (0.1 mL of saline; \(n = 12\)), the control secretome (0.1 mL equivalent of the 25-fold concentrated secretome obtained from \(10^5\) ASCs after 24 h culture in serum-free medium, \(n = 12\)), or the miR-150 secretome (0.1 mL equivalent of the 25-fold concentrated serum-free medium obtained from \(10^5\) ASCs that were transfected with miR-150, \(n = 12\)) two times a week for 1 week.

ELISA
Blood samples were collected from each mouse and centrifuged for 10 min at 9500 \(\times\) g, and serum was collected. The concentrations of mouse interleukin (IL)-6 and tumor necrosis factor (TNF)-\(\alpha\) were measured by sandwich enzyme-linked immunosorbent assay (ELISA) (Biolegend, San Diego, CA) according to the manufacturer’s instructions.

Statistical analysis
All data were analyzed using a standard software package (SPSS 11.0; SPSS Inc., Chicago, IL). All data are reported as the means ± standard deviations. Statistical comparison among groups was determined using the Kruskal–Wallis test. Probability values of \(P < 0.05\) were regarded as statistically significant.

Results
Effects of miR-150 transfection on the functionality of ASCs
We investigated whether miR-150 transfection impacted the functionality of ASCs, including surface marker expression and multilineage differentiation potential. MiR-150 transfection did not affect the gross morphology of cultured ASCs (Fig. 1a). MiR-150 transfection did not alter the expression of ASC surface markers, as determined by flow cytometry (Fig. 1b). MiR-150 transfection also did not impair the multilineage differentiation potential of ASCs, as demonstrated by the successful differentiation of miR-150-transfected ASCs into adipogenic, osteogenic, and chondrogenic cells (Fig. 1c, d).

Antifibrotic effects of the miR-150 secretome in an in vitro model of liver fibrosis
To clarify the posttransfection expression of miR-150 in ASCs, we measured the expression of miR-150 using realtime PCR after extracting the miRNAs from ASCs 24 h and 48 h after transfection. At 24 h posttransfection, decreased miR-150 expression was observed in miR-150-transfected ASCs, and increased miR-150 expression was observed in the exosomes of miR-150-transfected ASCs (\(P < 0.05\)) (Fig. 2a). However, at 48-h posttransfection, there was no mRNA expression in either miR-150-transfected ASCs or their exosomes (data not shown). These results suggest that miR-150 accumulated and was released in exosomes 24 h after transfection. In this experiment, the secretome obtained at 24 h after transfection was used; thus, miR-150 was expected to be present in the miR-150 secretome.

We transfected antifibrotic miR-150 into ASCs and determined the expression of fibrosis-related markers in the transfected cells. MiR-150-transfected ASCs expressed significantly lower levels of MMP2 mRNA than control ASCs, particularly 48 h after transfection (\(P < 0.05\)) (Fig. 2b). Additionally, miR-150-transfected ASCs expressed significantly lower levels of COL1A1 mRNA than control ASCs (\(P < 0.05\)).

Next, the miR-150 secretome was obtained from the conditioned media of miR-150-transfected ASCs after several purification steps that were described in the Methods section. We then established an in vitro model of liver fibrosis by treating human stellate cells (LX2 cells) with the hepatotoxic thioacetamide (TAA) (2.5 mM). The TAA-treated HSCs exhibited increased expression levels of fibrosis-related markers, such as TGF\(\beta\), Col1A1, and \(\alpha\)-SMA, than those of control HSCs. Subsequently, we added either the control or miR-150 secretome to either the control or TAA-treated HSCs and determined the expression of fibrosis-related markers. The miR-150 secretome resulted in a more significant reduction in the expression of these markers than that of the control secretome, particularly in TAA-treated HSCs (\(P < 0.05\)) (Fig. 2c).

Antifibrotic effects of the miR-150 secretome in an in vivo model of liver fibrosis
To validate the effects of the miR-150 secretome in vivo, we established a mouse model of liver fibrosis by subcutaneous injection of TAA (200 mg/kg) three times a week for 5 weeks. The mice were intravenously infused with normal saline (\(n = 12\)), the control secretome (\(n = 12\)), or the miR-150 secretome (\(n = 12\)) two times a week for
1 week (Fig. 3a). Serum samples were collected on the determined days; the mice were euthanized, and liver specimens were obtained on the 7th day.

RT-PCR revealed that infusion of either the control or miR-150 secretome significantly reduced the mRNA expression levels of MMP-2, α-SMA, and TGF-β1 in the liver compared to those of infusion of normal saline, particularly in mice with liver fibrosis (Fig. 3b) ($P < 0.05$).

In comparing the two secretome groups, the miR-150 secretome group had significantly lower mRNA expression levels of MMP-2 and TGF-β in the liver compared to those of the control secretome group ($P < 0.05$). There was no significant difference in the expression of α-SMA between the two secretome groups.

We then compared the expression of various proteins in each group by western blot analysis (Fig. 3c). The infusion
of the miR-150 secretome resulted in increased expression levels of PCNA, a proliferation marker, compared to the levels obtained by infusion of the control secretome ($P < 0.05$). Additionally, lower levels of fibrosis-related markers, such as $\alpha$-SMA, TGF-$\beta$1, MMP-2, and TIMP-1, were observed in liver specimens after infusion of the miR-150 secretome compared to those of infusion with the control secretome ($P < 0.05$).

Subsequently, we compared the serum levels of proinflammatory cytokines, including IL-6 and TNF-$\alpha$, among...
the groups (Fig. 4a). Secretome infusions significantly reduced the serum levels of IL-6 and TNF-α, and the reductions in cytokine levels were more significant after infusion of the the miR-150 secretome than the control secretome (P < 0.05). Subsequently, we compared the serum levels of albumin, aspartate transaminase (AST), and alanine transaminase (ALT) in each group (Fig. 4b). The serum albumin concentration was highest in the miR-150 secretome group, followed by the control secretome group (P < 0.05). The serum levels of liver enzymes (AST and ALT) were significantly increased in the TAA group. Of them, the miR-150 secretome group showed the lowest levels of these liver enzymes, followed by the control secretome group (P < 0.05). We next performed Sirius red and Masson trichrome staining to determine the degree of liver fibrosis (Fig. 4c). Both stains demonstrated the antifibrotic effects of secretome infusion; moreover, the miR-150 secretome group had significantly greater improvement in fibrosis than that of the control secretome group (P < 0.05).

Immunohistochemistry and liquid chromatography-mass spectrometry analysis of secretome components

To determine the effects of the miR-150 secretome on the fibrotic liver, we used immunohistochemistry (IHC) to evaluate liver specimens. Antibodies against α-SMA, albumin, and SOD were used to determine the effects of the miR-150 secretome on liver fibrosis, hepatic synthesis function, and antioxidant activity, respectively. The fibrotic livers were characterized by increased levels of α-SMA and reduced levels of albumin and SOD (Fig. 5a). Based on α-SMA IHC results, infusion of the miR-150 secretome significantly reduced the expression of α-SMA in both fibrotic and normal livers. Based on albumin IHC results, infusion of the miR-150 secretome significantly increased the expression of albumin in both normal and fibrotic livers. Finally, based on SOD IHC results, infusion of the miR-150 secretome significantly decreased the expression of SOD in both normal and fibrotic livers. Taken together, the miR-150 secretome has the potential to enhance hepatic synthesis functions and antioxidant activity, as well as to reduce liver fibrosis.

Finally, liquid chromatography-mass spectrometry (LC-MS) was used to determine the components in the conditioned medium. The protein components in the control secretome were compared with those in the miR-150 secretome. LC/MS analysis of both sets of components detected many differences in protein expression in both groups (Fig. 5b). For example, the miR-150 secretome contained a considerably lower level of vimentin (a profibrogenic protein) and had considerably higher expression of PTX3 (an antifibrogenic protein) compared to those of the control secretome.

Discussion

This study validated the antifibrotic and anti-inflammatory effects of the secretome released from miR-150-transfected ASCs. Our in vitro and in vivo experiments consistently demonstrated that miR-150 transfection improved the antifibrotic and anti-inflammatory properties of ASCs. In particular, intravenous infusion of the miR-150 secretome in mice with liver fibrosis resulted in (1) abrogation of the elevated systemic inflammatory cytokines, such as IL-6 and TNF-α, (2) a significant reduction in liver fibrosis, and (3) increased expression of markers of liver cell proliferation and liver antioxidant activities. Taken together, these findings suggest that miR-150 transfection in ASCs has the potential to induce the release of a secretome with improved antifibrotic, proliferative, and antioxidant effects than that of a naïve secretome.

MiR-150 is a representative antifibrotic miRNA. A recent investigation revealed several mechanisms by which miR-150 exerts antifibrotic effects. First, miR-150 inhibits HSC activation by inhibiting c-myb expression. C-myb is a protooncogene that encodes a transcription factor that is involved in the proliferation, differentiation, and survival of hematopoietic cells. C-myb is also
expressed by activated HSCs and has a substantial role in the development of fibrosis. In addition, c-myb has an established role in oxidative stress-induced production of type I collagen by activated HSCs. Therefore, inhibiting c-myb by miR-150 exerts antifibrotic effects. Additionally, miR-150 reduces type I and IV collagen by directly binding to Sp1 and COL4A4, respectively, without the involvement of factors upstream of the TGF-β/Smad pathway. Specifically, miR-150 targets the 3′ UTR region of Sp1. The interaction between miR-150 and the target regions in Sp1 leads to a reduction in COL1A1, which is responsible for producing type I collagen. MiR-150 also...
interacts with the 3' UTR of COL4A4, which encodes type IV collagen in fibrotic livers. Taken together, miR-150 is an antifibrogenic miRNA that not only inhibits the activation of HSCs but also reduces the production of type I and type IV collagen by HSCs.

Overall, treatment with the miR-150 secreteme reduced the expression of profibrogenic markers, such as α-SMA, MMP2, and TGF-β, more than that of the control secreteme in both in vitro and in vivo models of liver fibrosis. These changes were observed at both the RNA and protein levels, except for α-SMA. While the mRNA expression of α-SMA was similarly decreased in both the control and miR-150 secreteme groups, the protein expression of α-SMA was significantly lower in the miR-150 secreteme group than in the control secreteme group in both in vitro and in vivo experiments due to unknown reasons. Further study is needed to determine the precise cause of this discrepancy.

In this study, we transfected ASCs but not HSCs with miR-150. We hypothesized that miR-150 has the potential to reprogram ASCs to release materials with improved antifibrotic properties. The release of miR-150 from miR-150-transfected ASCs is correlated with exosomes. At 24-h posttransfection, decreased miR-150 expression in miR-150-transfected ASCs and increased miR-150 expression in the exosomes of miR-150-transfected ASCs were observed. These results suggest that miR-150 accumulated and was released in exosomes 24 h after transfection. The miR-150 secreteme was thus obtained at 24 h of transfection to include these kinds of exosomes. Intravenous infusion of the miR-150 secreteme significantly reduced the expression of TGF-β1 in the livers of mice with liver fibrosis, suggesting that the miR-150 secreteme has the potential to inhibit TGF-β1 signaling.

TGF-β/Smad signaling is an attractive therapeutic target for the treatment of liver fibrosis. Several anti-TGF-β strategies are currently available, including the administration of anti-TGF-β-neutralizing antibodies, soluble TβRs, and small molecule TβR kinase inhibitors. We think that the miR-150 secreteme has the potential to become a prominent anti-TGF-β strategy. TGF-β is the most potent factor that accelerates liver fibrosis in a number of ways, including by promoting HSC activation, stimulating collagen gene transcription, and inhibiting MMP expression. Under the inflammatory microenvironment of the liver, TGF-β is secreted not only by platelets and Kupffer cells but also by activated HSCs themselves. TGF-β is also highly expressed in activated HSCs. TGF-β first binds to the type II TGF-β receptor on the surface of HSCs. It recruits and phosphorylates the type I receptor, which in turn phosphorylates Smad2 and Smad3. TGF-β then forms a complex with Smad4, which is translocated from the cytoplasm to the nucleus, subsequently stimulating the transcription of genes that promote fibrogenesis. Our results suggest that interfering with TGF-β/Smad signaling is the principal mechanism of action of the miR-150 secreteme.

There were considerable differences in the protein components of the control and miR-150 secretemes. Certain protein components were increased and the others were not changed or decreased in the miR-150 secreteme compared to those of the control secreteme. It is thought that the total number of these changes contributes to the robust antifibrogenic effect of the miR-150 secreteme. Specifically, the miR-150 secreteme contained a considerably lower levels of vimentin (a profibrogenic protein) and considerably higher expression of PTX3 (an antifibrogenic protein) compared to those of the control secreteme. Vimentin is an essential element of inflammation and fibrosis. Walker et al. showed that vimentin mediates the transition of mesenchymal leader cells to a myofibroblast phenotype, facilitating fibrosis in wound repair, while vimentin deficiency resulted in a blunted inflammatory response. Vimentin is also a key regulator of the NLRP3 inflammasome, promoting lung inflammation and fibrosis. In addition, PTX3 inhibits inflammation and leukocyte adhesion and transmigration. PTX3 produced by monocytes/macrophages abolishes neutrophil recruitment and oxidative bursts. PTX3 also cooperates with
Fig. 4 Determination of systemic inflammation and a histological assessment of liver specimens. a ELISA results demonstrating the serum levels of proinflammatory mediators, including IL-6 and TNF-α, in each group. Secretome infusions significantly reduced the serum levels of IL-6 and TNF-α in mice with liver fibrosis. When comparing both groups, miR-150 secretome infusion induced more significant reductions in these cytokines than those of the control secretome infusion group. b Serum levels of albumin, AST, and ALT in each group. The serum albumin concentration was highest in the miR-150 secretome group, followed by the control secretome group. Of the TAA-treated groups, the miR-150 secretome group showed the lowest levels of these liver enzymes, followed by the control secretome group. c Sirius red (Top left) and Masson trichrome (Bottom left) staining showing the degree of fibrosis. Both stains demonstrated that infusion of the miR-150 secretome decreased liver fibrosis more than that of secretion of the control secretome. (Right) Comparison of fibrotic areas in each group. Percentages of fibrotic areas were measured using NIH ImageJ and are expressed as relative values to those in normal livers. The values are presented as the mean ± standard deviation of three independent experiments. *P < 0.05. ALT alanine transaminase, AST aspartate transaminase, Sec the secretome obtained from ASCs after 48 h of incubation, TNF-α tumor necrosis factor-α, t-Sec the secretome released from miR-150-transfected ASCs.
Fig. 5 (See legend on next page.)
the adaptive immune system in defense against infectious agents by developing a protective Th1/Treg immune response. Thus, identifying the roles of the altered protein components in the miR-150 secretome is expected to help identify antifibrogenic materials in the future.

In conclusion, our in vitro and in vivo experiments indicate that the miR-150 secretome is superior to the naïve secretome in terms of ameliorating liver fibrosis, minimizing systemic inflammatory responses, and promoting antioxidant activities of the liver. Accordingly, we think that miR-150 transfection has the potential to induce the release of secretory materials from ASCs that have enhanced antifibrotic, proliferative, and antioxidant properties. We also showed that interfering with TGF-β/Smad signaling may be the principal mechanism of action of the miR-150 secretome. We thus conclude that the miR-150 secretome is a potential anti-TGF-β strategy against liver fibrosis.

Acknowledgements

We thank Byung-Rok Do and Ji-Hyang Kim of Hurim BioCell Company for providing human ASCs and technical assistance. We would like to thank Hye-Jung Kim and Ji-Hye Park for photoshop work and support for data processing. The authors wish to acknowledge the financial support of the Catholic Medical Center Research Foundation provided in the 2018 program year.

Author details

1Department of Surgery, Yonsei University St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea. 2Department of Surgery, Uijeongbu St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea. 3Catholic Central Laboratory of Surgery, Institute of Biomedical Industry, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea. 4Department of Surgery, Eunpeong St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea. 5Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea.

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Ameer, M. E. M. et al. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. Eur. J. Gastroen. Hepat. 23, 936–941 (2011).
2. Amin, M. A. et al. Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study. Clin. Transpl. 27, 607–612 (2013).
3. El-Ansary, M. et al. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HIV-induced liver cirrhosis. Stem Cell Rev. Rep. 8, 972–981 (2012).
4. Jang, Y. O. et al. Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int. 34, 33–41 (2014).
5. Kharaizah, P. et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase II clinical trial. Eur. J. Gastroen. Hepat. 21, 1199–1205 (2009).
6. Mohamadnejad, M. et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch. Iran. Med. 10, 459–466 (2007).
7. Peng, L. et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatol. 54, 820–828 (2011).
8. Makridakis, M., Roubelakis, M. G. & Vlahou, A. Stem cells: insights into the secretome. Bba-Proteins Proteom. 1834, 2380–2384 (2013).
9. Salgado, A. J. et al. Mesenchymal stem cells secreteome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities. Front. Cell Neurosci. 9, 249 (2015).
10. Assuncao-Silva, R. C. et al. Exploring the impact of the secretome of MSCs isolated from different tissue sources on neuronal differentiation and axonal growth. Biochimie 155, 83–91 (2018).
11. Attar-Schneider, O., Drucker, L. & Gottfried, M. The effect of mesenchymal stem cells’ secretome on lung cancer progression is contingent on their origin: primary or metastatic niche. Lab Invest. 98, 1549–1561 (2018).
12. Belle, B. et al. Adipose tissue-derived extracellular fraction characterization: biological and clinical considerations in regenerative medicine. Stem Cell Res. Ther. 9, 207 (2018).
13. Gomes, E. D., de Castro, J. V., Costa, B. M. & Salgado, A. J. The impact of Mesenchymal Stem Cells and their secreteome as a treatment for gliomas. Biochimie 155, 59–66 (2018).
14. Kim, H. K. et al. A subset of paracrine factors as efficient biomarkers for predicting vascular regenerative efficacy of mesenchymal stromal/stem cells. Stem Cells 37, 77–88 (2019).
15. Merelles, L. D., Fontes, A. M., Covas, D. T. & Caplan, A. I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth F. R. 20, 419–427 (2009).

Received: 17 June 2019 Revised: 13 December 2019 Accepted: 29 January 2020.
Published online: 9 March 2020
16. Mohammadipoor, A., Antebi, B., Batchinsky, A. I. & Canco, L. C. Therapeutic potential of products derived from mesenchymal stem/stromal cells in pulmonary disease. Resp. Res. 19, 1–14 (2018).
17. Wazak, P. et al. Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats. Stem Cells Dev. 21, 2789–2797 (2012).
18. Lee, S. C., Jeong, H. J., Lee, S. K. & Kim, S. J. Lipopolysaccharide preconditioning of adipose-derived stem cells improves liver-regenerating activity of the secretome. Stem Cell Res. Ther. 6, 75 (2015).
19. Lee, S. C., Jeong, H. J., Lee, S. K. & Kim, S. J. Hypoxic conditioned medium from human adipose-derived stem cells promotes mouse liver regeneration through JAK/STAT3 signaling. Stem Cell Transl. Med. 5, 816–825 (2016).
20. Lee, S. C., Kim, J. O. & Kim, S. J. Secretome from human adipose-derived stem cells protects mouse liver from hepatic ischemia-reperfusion injury. Surgery 157, 934–943 (2015).
21. Lee, S. C. et al. Determination of optimized oxygen partial pressure to maximize the liver regenerative potential of the secretome obtained from adipose-derived stem cells. Stem Cell Res. Ther. 8, 181 (2017).
22. Lee, S. K., Lee, S. C. & Kim, S. J. A novel cell-free strategy for promoting mouse liver regeneration: utilization of a conditioned medium from adipose-derived stem cells. Hepatol. Int. 9, 310–320 (2015).
23. Lee, S. M., Lee, S. C. & Kim, S. J. Contribution of human adipose tissue-derived stem cells and the secretome to the skin allograft survival in mice. J. Surg. Res. 188, 280–289 (2014).
24. Przybytek, E., Kiennig, G., Brinker, M. G. L. & Hammsen, M. C. Adipose stromal cells primed with hypoxia and inflammation enhance cardiomyocyte proliferation rate in vitro through STAT3 and Erk1/2. J. Transl. Med. 11, 39 (2013).
25. Chen, W. N. et al. miR-150 deficiency protects against FAS-induced acute liver injury in mice through regulation of AKT. PLoS ONE 10, e0132734 (2015).
26. Deng, P. et al. MicroRNA-150 inhibits the activation of cardiac fibroblasts by regulating c-Myc. Cell Physiol. Biochem. 38, 2103–2122 (2016).
27. Huang, X. L. et al. MicroRNA-150: a potential regulator in pathogens infection and autoimmune diseases. Autoimmunity 48, 503–510 (2015).
28. Li, Y. et al. MicroRNA-150 relieves vascular remodeling and fibrosis in hypoxia-induced pulmonary hypertension. Biomed. Pharmacother. 109, 1740–1749 (2019).
29. Venugopal, S. K. et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am. J. Physiol.-Gastrointest. Liver Physiol. 298, G101–G106 (2010).
30. You, K. et al. MicroRNA-125b promotes hepatic stellate cell activation and liver fibrosis by activating RhoA signaling. Mol. Ther.-Nucl. Acids 12, 57–66 (2018).
31. Zheng, J. J. et al. Activation of hepatic stellate cells is suppressed by microRNA-150. Int. J. Mol. Med. 32, 17–24 (2013).
32. An, S. Y. et al. Valproic acid promotes differentiation of hepatocyte-like cells from whole human umbilical cord-derived mesenchymal stem cells. Tissue Cell 46, 127–135 (2014).
33. Swoklos, S., Constantinescu, A. & Connor, C. J. Alginate-encapsulation for the improved hypothymic preservation of human adipose-derived stem cells. Stem Cell Transl. Med. 5, 339–349 (2016).
34. Shen-Ong, G. L. The myb oncogene. Biochem. Biophys. Acta 1032, 39–52 (1990).
35. Kitada, T. et al. Hepatic expression of c-Myb in chronic human liver disease. Hepatology 26, 1506–1512 (1997).
36. Lee, K. S., Buck, M., Houglum, K. & Chojkier, M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J. Clin. Invest. 96, 2461–2468 (1995).
37. Biernacka, A., Dobaczewski, M. & Frangogiannis, N. G. TGF-beta signaling in fibrosis. Growth Factors 29, 196–202 (2011).
38. Inagaki, Y. & Otakazi, I. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 56, 284–292 (2007).
39. Pinzani, M. & Macias-Barragan, J. Update on the pathophysiology of liver fibrosis. Expert Rev. Gastroenterol. Hepatol. 4, 459–472 (2010).
40. Walker, J. L., Bleaken, B. M., Romisher, A. R., Alnawit, A. A. & Menko, A. S. In wound repair vimentin mediates the transition of mesenchymal leader cells to a myofibroblast phenotype. Mol. Biol. Cell 29, 1555–1570 (2018).
41. Kunis, P., Holubcova, Z., Kolarova, M. & Krejcek, J. Pentraxin 3 (PTX3): an endogenous modulator of the inflammatory response. Mediators Inflamm. 2012, 920517 (2012).
42. Deibar, L. et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat. Immunol. 11, 328–334 (2010).
43. Tadagavadi, R. K., Wang, W. W. & Ramesh, G. Netrin-1 regulates Th1/Th2/Th17 cytokine production and inflammation through UNC5B receptor and protects kidney against ischemia-reperfusion injury. J. Immunol. 185, 3750–3758 (2010).